Genprex (GNPX) Competitors $2.02 -0.13 (-6.05%) (As of 11/4/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends GNPX vs. AYTU, UBX, APRE, CYTH, MEIP, LSB, CMMB, NNVC, FNCH, and TNXPShould you be buying Genprex stock or one of its competitors? The main competitors of Genprex include Aytu BioPharma (AYTU), Unity Biotechnology (UBX), Aprea Therapeutics (APRE), Cyclo Therapeutics (CYTH), MEI Pharma (MEIP), Lakeshore Biopharma (LSB), Chemomab Therapeutics (CMMB), NanoViricides (NNVC), Finch Therapeutics Group (FNCH), and Tonix Pharmaceuticals (TNXP). These companies are all part of the "pharmaceutical products" industry. Genprex vs. Aytu BioPharma Unity Biotechnology Aprea Therapeutics Cyclo Therapeutics MEI Pharma Lakeshore Biopharma Chemomab Therapeutics NanoViricides Finch Therapeutics Group Tonix Pharmaceuticals Genprex (NASDAQ:GNPX) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk. Is GNPX or AYTU more profitable? Genprex has a net margin of 0.00% compared to Aytu BioPharma's net margin of -19.56%. Aytu BioPharma's return on equity of -51.31% beat Genprex's return on equity.Company Net Margins Return on Equity Return on Assets GenprexN/A -318.57% -224.95% Aytu BioPharma -19.56%-51.31%-12.40% Does the media favor GNPX or AYTU? In the previous week, Genprex had 3 more articles in the media than Aytu BioPharma. MarketBeat recorded 3 mentions for Genprex and 0 mentions for Aytu BioPharma. Aytu BioPharma's average media sentiment score of 0.00 beat Genprex's score of -0.01 indicating that Aytu BioPharma is being referred to more favorably in the news media. Company Overall Sentiment Genprex Neutral Aytu BioPharma Neutral Does the MarketBeat Community believe in GNPX or AYTU? Aytu BioPharma received 56 more outperform votes than Genprex when rated by MarketBeat users. Likewise, 67.11% of users gave Aytu BioPharma an outperform vote while only 65.25% of users gave Genprex an outperform vote. CompanyUnderperformOutperformGenprexOutperform Votes19965.25% Underperform Votes10634.75% Aytu BioPharmaOutperform Votes25567.11% Underperform Votes12532.89% Which has more volatility & risk, GNPX or AYTU? Genprex has a beta of -1.32, suggesting that its share price is 232% less volatile than the S&P 500. Comparatively, Aytu BioPharma has a beta of -1.4, suggesting that its share price is 240% less volatile than the S&P 500. Do analysts prefer GNPX or AYTU? Genprex currently has a consensus target price of $10.00, suggesting a potential upside of 395.05%. Given Genprex's higher probable upside, analysts plainly believe Genprex is more favorable than Aytu BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genprex 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Aytu BioPharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Do insiders & institutionals believe in GNPX or AYTU? 14.1% of Genprex shares are held by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are held by institutional investors. 8.5% of Genprex shares are held by insiders. Comparatively, 2.8% of Aytu BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has stronger valuation & earnings, GNPX or AYTU? Aytu BioPharma has higher revenue and earnings than Genprex. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenprexN/AN/A-$30.86MN/AN/AAytu BioPharma$81M0.15-$15.84M-$2.86-0.67 SummaryAytu BioPharma beats Genprex on 8 of the 14 factors compared between the two stocks. Ad Investing Daily626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trader has done over the past 8 years—closing 647 trades, with an unbelievable 97% win rate. Now, for the first time, he's breaking his silence and revealing his personal technique for success.Click here to watch our exclusive interview and uncover his personal technique Get Genprex News Delivered to You Automatically Sign up to receive the latest news and ratings for GNPX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNPX vs. The Competition Export to ExcelMetricGenprexPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.23M$6.74B$5.02B$8.40BDividend YieldN/A7.94%7.52%4.16%P/E RatioN/A11.86128.6616.67Price / SalesN/A269.811,718.2576.46Price / CashN/A46.0936.9133.53Price / Book0.405.304.595.18Net Income-$30.86M$150.82M$114.09M$223.67M7 Day Performance-26.28%-1.09%110.28%2.59%1 Month Performance476.16%15.18%124.25%8.66%1 Year Performance-84.17%36.68%154.82%28.23% Genprex Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNPXGenprex4.2236 of 5 stars$2.02-6.0%$10.00+395.0%-84.2%$5.23MN/A0.0020Upcoming EarningsAYTUAytu BioPharma0.7691 of 5 stars$1.94+1.0%N/A-34.1%$11.91M$81.00M-0.68160Upcoming EarningsUBXUnity Biotechnology3.7607 of 5 stars$1.31-3.7%$6.67+408.9%-38.8%$22.07M$240,000.00-0.6660Upcoming EarningsNews CoverageAPREAprea Therapeutics2.8651 of 5 stars$3.92+0.3%$15.50+295.4%-0.7%$21.29M$580,000.00-1.297CYTHCyclo Therapeutics2.6504 of 5 stars$0.72-4.0%$0.95+31.7%-27.7%$20.71M$1.08M-0.829Upcoming EarningsMEIPMEI Pharma4.5068 of 5 stars$3.07-1.0%$7.00+128.0%-57.0%$20.45M$65.30M1.15100Gap DownLSBLakeshore Biopharma0.3723 of 5 stars$2.16-7.3%N/AN/A$20.11M$80.82M0.00773Gap DownCMMBChemomab Therapeutics2.5388 of 5 stars$1.38-2.8%$5.67+310.6%+92.1%$19.82MN/A-1.2120Gap UpNNVCNanoViricidesN/A$1.42-0.7%N/A+28.9%$19.81MN/A-2.0320FNCHFinch Therapeutics GroupN/A$12.15+1.3%N/A+199.0%$19.56M$110,000.00-1.38190TNXPTonix Pharmaceuticals3.1896 of 5 stars$0.14-6.7%$53.50+38,306.3%-99.1%$19.12M$7.77M0.00103Analyst ForecastNews CoverageGap Up Related Companies and Tools Related Companies AYTU Competitors UBX Competitors APRE Competitors CYTH Competitors MEIP Competitors LSB Competitors CMMB Competitors NNVC Competitors FNCH Competitors TNXP Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GNPX) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | SponsoredCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genprex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genprex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
